奥沙利铂联合卡培他滨治疗晚期结肠癌患者的临床疗效及神经毒性的观察
|
摘要
目的研究晚期结肠癌患者采取奥沙利铂与卡培他滨治疗的价值及神经毒性。方法选择我院2013年12月～2017年12月纳入60例晚期结肠癌患者,按照随机数字表法分为两组,每组各30例,研究组采取奥沙利铂与卡培他滨,对照组采取卡培他滨,对比两组治疗结果。结果研究组总疾病控制率86.67%高于对照组70.00%,差异有统计学意义(P <0.05);研究组神经毒性情况与对照组比较,差异无统计学意义(P> 0.05);治疗前两组生活质量评分比较,差异无统计学意义(P> 0.05),治疗后研究组评分高于对照组,差异有统计学意义(P <0.05)。结论晚期结肠癌患者采取奥沙利铂与卡培他滨治疗效果明显,促进病灶缩小,改善生活质量,为预后提供保障。
Objective To study the value and neurotoxicity of oxaliplatin and capecitabine in patients with advanced colon cancer. Methods Sixty patients with advanced colon cancer who were included in our hospital from December 2013 to December 2017 were randomly divided into two groups,30 patients in each group,the research group was treated with oxaliplatin and capecitabine,while the control group was treated with capecitabine,the results of the two groups were compared. Results The total disease control rate in the research group was 86.67% higher than 70.00% in the control group(P < 0.05);There was no significant difference in neurotoxicity between the research group and the control group(P > 0.05);There was no significant difference in quality of life scores between the two groups before treatment(P > 0.05),and the score of the research group was higher than that of the control group after treatment(P < 0.05). Conclusion Oxaliplatin and capecitabine are effective in the treatment of advanced colon cancer,which can shrink the lesion area,improve the quality of life and provide a guarantee for the prognosis.
Objective To study the value and neurotoxicity of oxaliplatin and capecitabine in patients with advanced colon cancer. Methods Sixty patients with advanced colon cancer who were included in our hospital from December 2013 to December 2017 were randomly divided into two groups,30 patients in each group,the research group was treated with oxaliplatin and capecitabine,while the control group was treated with capecitabine,the results of the two groups were compared. Results The total disease control rate in the research group was 86.67% higher than 70.00% in the control group(P < 0.05);There was no significant difference in neurotoxicity between the research group and the control group(P > 0.05);There was no significant difference in quality of life scores between the two groups before treatment(P > 0.05),and the score of the research group was higher than that of the control group after treatment(P < 0.05). Conclusion Oxaliplatin and capecitabine are effective in the treatment of advanced colon cancer,which can shrink the lesion area,improve the quality of life and provide a guarantee for the prognosis.
引文
[1]毛跃伟,杨松鹏,高磊,等.奥沙利铂联合卡培他滨治疗晚期结肠癌的临床研究[J].中国临床药理学杂志,2016,32(14):1286-1288,1292.
[2]宋涛,王铎,肖嘎,等.卡培他滨联合奥沙利铂术前新辅助化疗对结肠癌的临床疗效[J].贵州医科大学学报,2017,42(9):1107-1110.
[3]王秀芳.奥沙利铂联合卡培他滨对老年结肠癌患者安全性、预后及Bcl-2、环氧化酶-2、癌胚抗原的影响[J].中国老年学杂志,2018,38(5):1100-1102.
[4]杜敏娟.卡培他滨联合奥沙利铂治疗晚期结肠癌的临床疗效观察[J].中国卫生标准管理,2015,6(20):102-103.
[5]师广勇.卡培他滨加用奥沙利铂联合治疗晚期结肠癌的临床疗效和毒副作用分析[J].实用癌症杂志,2018,33(2):305-307.
[6]王开银,林凯,胡廷辉,等.卡培他滨联合奥沙利铂治疗晚期及复发性结肠癌的临床疗效及副作用分析[J].北方药学,2016,13(9):95.
[7]雷新键,郑款恒,李峰,等.卡培他滨联合奥沙利铂治疗晚期结肠癌的疗效观察[J].北方药学,2016,13(11):37.
[8]宋超,赵晶,高超,等.卡培他滨节拍化疗联合奥沙利铂传统化疗在晚期结肠癌中的研究[J].徐州医科大学学报,2017,37(12):790-793.
[9]孙春花,徐晓俊,过雪丹,等.结肠癌CapeOX方案新辅助化疗的临床研究[J].中国肿瘤外科杂志,2015,7(6):387-389,393.
[10]庄业忠,林佳锐,黄棉生,等.奥沙利铂联合卡培他滨新辅助化疗治疗可切除局部晚期结肠腺癌的疗效及安全性-病例对照分析[J].岭南现代临床外科,2016,16(3):266-269.
[2]宋涛,王铎,肖嘎,等.卡培他滨联合奥沙利铂术前新辅助化疗对结肠癌的临床疗效[J].贵州医科大学学报,2017,42(9):1107-1110.
[3]王秀芳.奥沙利铂联合卡培他滨对老年结肠癌患者安全性、预后及Bcl-2、环氧化酶-2、癌胚抗原的影响[J].中国老年学杂志,2018,38(5):1100-1102.
[4]杜敏娟.卡培他滨联合奥沙利铂治疗晚期结肠癌的临床疗效观察[J].中国卫生标准管理,2015,6(20):102-103.
[5]师广勇.卡培他滨加用奥沙利铂联合治疗晚期结肠癌的临床疗效和毒副作用分析[J].实用癌症杂志,2018,33(2):305-307.
[6]王开银,林凯,胡廷辉,等.卡培他滨联合奥沙利铂治疗晚期及复发性结肠癌的临床疗效及副作用分析[J].北方药学,2016,13(9):95.
[7]雷新键,郑款恒,李峰,等.卡培他滨联合奥沙利铂治疗晚期结肠癌的疗效观察[J].北方药学,2016,13(11):37.
[8]宋超,赵晶,高超,等.卡培他滨节拍化疗联合奥沙利铂传统化疗在晚期结肠癌中的研究[J].徐州医科大学学报,2017,37(12):790-793.
[9]孙春花,徐晓俊,过雪丹,等.结肠癌CapeOX方案新辅助化疗的临床研究[J].中国肿瘤外科杂志,2015,7(6):387-389,393.
[10]庄业忠,林佳锐,黄棉生,等.奥沙利铂联合卡培他滨新辅助化疗治疗可切除局部晚期结肠腺癌的疗效及安全性-病例对照分析[J].岭南现代临床外科,2016,16(3):266-269.